Bellafill: The Long-Lasting Dermal Filler for Folds and Acne Scars

Bellafill is an FDA-approved injectable dermal filler composed of polymethyl methacrylate (PMMA) microspheres suspended in a bovine collagen gel carrier. The U.S. Food and Drug Administration first approved Bellafill in 2006 for nasolabial fold correction and expanded its indication in 2014 to include moderate to severe atrophic facial acne scars on the cheeks in patients over 21. Unlike resorbable hyaluronic acid fillers that dissolve within months, Bellafill delivers both immediate volume restoration and long-term collagen stimulation, with clinical evidence supporting results lasting up to five years.

What Bellafill Is and How It Works

Bellafill works through a two-phase mechanism: bovine collagen in the formula provides immediate volume and wrinkle correction upon injection, while non-resorbable PMMA microspheres act as a scaffold that stimulates the body’s own collagen production over time for lasting structural support.

The formula consists of 20% PMMA microspheres, 30 to 50 microns in diameter, suspended in a water-based carrier gel containing 3.5% bovine collagen, buffered isotonic water, 0.3% lidocaine hydrochloride for comfort, phosphate buffer, and sodium chloride. The body gradually absorbs the bovine collagen component and replaces it with endogenous collagen anchored around the PMMA microspheres, which remain in place permanently. Because the microspheres are non-resorbable, Bellafill cannot be dissolved with hyaluronidase and can only be removed surgically if necessary. Research published in Aesthetic Plastic Surgery confirms that the PMMA microspheres in Bellafill are third-generation formulations with more uniform sizing than predecessor products, which reduces the incidence of granuloma formation compared to earlier PMMA fillers.

FDA-Approved Indications for Bellafill

Bellafill holds two FDA-approved indications: correction of moderate to severe nasolabial folds (smile lines) in adults, and treatment of moderate to severe atrophic, distensible facial acne scars on the cheeks in patients over the age of 21 years.

Nasolabial fold correction represents Bellafill’s primary approved use, targeting the lines that run from the nose corners to the mouth corners. The 5-year Post-Approval Study on nasolabial folds with 1,008 patients established the long-term safety profile of Bellafill for this indication, making it one of the most extensively studied dermal fillers in the U.S. market. The 2014 acne scar indication targets distensible, atrophic scars on the cheeks, which are pitted depressions caused by loss of dermal collagen following inflammatory acne. Bellafill lifts and fills these depressed scars by restoring volume beneath the scar base. According to a classification framework published in the Journal of the American Academy of Dermatology, atrophic acne scars represent one of the most treatment-resistant categories of post-acne sequelae, making a long-duration filler option clinically meaningful for affected patients.

Off-Label Uses of Bellafill

Beyond its two FDA-approved indications, Bellafill has been used off-label by trained practitioners for malar augmentation, chin contouring, jaw angle definition, tear trough correction, temporal wasting, lip augmentation, and non-surgical rhinoplasty, with clinical studies reporting favorable safety profiles in these applications.

A retrospective clinical review published in a peer-reviewed plastic surgery journal covering 212 patients and 842 syringes administered between 2014 and 2017 found that off-label Bellafill use across multiple facial areas produced high subjective patient satisfaction at 2 years with an acceptable adverse event profile. Common off-label sites included the malar regions for cheek volume restoration, temporal hollows, tear trough deformities, and the chin and jaw for structural augmentation. Practitioners using Bellafill off-label apply the same pre-treatment allergy screening and injection technique standards as for approved indications. Patients considering off-label Bellafill applications should discuss the distinction between approved and investigational use with their provider before proceeding.

Bellafill Treatment Procedure

Bellafill treatment is an in-office injectable procedure typically completed in 15 to 60 minutes depending on the number and size of treatment areas, with results visible immediately after injection and no required downtime.

Before receiving Bellafill, patients undergo an allergy skin test to identify potential reactions to bovine collagen or lidocaine. The skin test involves a small intradermal injection on the forearm, which is evaluated at four weeks for any allergic response. Patients who test positive are not candidates for Bellafill. At the treatment appointment, a licensed practitioner injects Bellafill using an ultrafine needle into the targeted areas, then molds the material to achieve the desired contour. The lidocaine within the formula reduces discomfort during injection. Patients may apply an ice pack to the treatment site afterward for swelling or mild discomfort. Most return to normal activities immediately following the session. Practitioners may recommend more than one treatment session for optimal correction, particularly in patients with deep nasolabial folds or multiple acne scars. The role of collagen in skin repair and aging has been an active area of research that informs the biostimulatory rationale behind Bellafill’s PMMA scaffold mechanism.

Duration of Results

Bellafill results for nasolabial fold correction last up to five years for most patients, supported by the FDA’s 5-year Post-Approval Study. Results for acne scar treatment typically persist for one year or longer, with some patients reporting permanent improvement.

The longevity of Bellafill sets it apart from the majority of dermal fillers on the market. Hyaluronic acid fillers generally require retreatment every four to six months, while Bellafill’s PMMA microsphere matrix sustains the collagen scaffold for multi-year periods. The 5-year post-approval study involving 1,008 nasolabial fold patients provides the strongest clinical durability evidence for any dermal filler currently approved in the United States. For acne scar patients, results vary based on scar depth and the individual’s collagen remodeling capacity, but clinical experience indicates that many patients maintain meaningful improvement for well beyond the initial 12 months. Bellafill is sometimes described as a semi-permanent or permanent filler because its results have only been formally studied to the five-year mark, though the PMMA microspheres themselves do not degrade in tissue.

Candidate Criteria and Contraindications

Bellafill is appropriate for adults over 21 with nasolabial folds or atrophic cheek acne scars who have no history of bovine collagen or lidocaine allergy, no bleeding disorders, and no tendency toward excessive or irregular scarring such as keloids.

Patients should disclose their complete medication history before treatment. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) increase bleeding and bruising risk at injection sites and may need to be paused before treatment. Patients on immunosuppressive therapy, including those managing organ transplant rejection, rheumatoid arthritis, psoriasis, inflammatory bowel disease, or cancer-related treatments, face elevated infection risk and require individualized assessment. Bellafill must not be implanted into blood vessels; intra-vascular injection can cause vascular occlusion, infarction, or emboli. The safety of Bellafill has not been established for pregnant or breastfeeding women. Patients who have received other dermal fillers within the preceding six months should inform their provider, as interactions between filler materials can complicate treatment planning.

Side Effects and Safety Profile

Common Bellafill side effects include temporary swelling, redness, bruising, and mild discomfort at injection sites, typically resolving within one to seven days. Less common effects include lumps, papules, persistent redness, and increased sensitivity. Granulomas are rare and treatable.

The 5-year Post-Approval Study involving over 1,000 patients established the long-term safety of Bellafill for nasolabial fold treatment at a clinical evidence level that no other injectable filler currently matches. Bruising at injection sites typically clears within three to seven days. Papules or small lumps that develop more than one month after injection may persist and should be reported to the treating provider. Granuloma formation, the rarest significant adverse event, involves small inflammatory nodules that a licensed physician can treat. Because the PMMA microspheres are non-resorbable, any adverse structural outcomes cannot be dissolved and may require surgical management in rare cases. Patients should alert their provider immediately if they observe unusual skin reactions, signs of vascular compromise such as blanching or extreme pain, or any progressive swelling in the weeks following treatment. The mandatory pre-treatment allergy skin test substantially reduces but does not eliminate the risk of allergic reaction. Researchers studying drug safety profiles and long-term study design have noted the Bellafill post-approval safety study as an example of rigorous post-market surveillance methodology.

Cost and Provider Selection

Bellafill is priced per syringe, with costs varying by geographic location, provider experience, and number of syringes required. The American Society of Plastic Surgeons has cited an approximate per-syringe reference cost, and patients should seek treatment from a board-certified dermatologist or cosmetic surgeon with documented Bellafill training.

Because Bellafill results are long-lasting and the product is non-reversible, provider selection carries greater weight than with temporary fillers. Prospective patients should verify board certification in dermatology, plastic surgery, or a related specialty, request before-and-after photographs from the provider’s Bellafill cases, and ensure the clinic follows the mandatory skin test protocol. Patients who are considering Bellafill after experiencing unsatisfactory results from shorter-duration fillers may benefit from reviewing the range of collagen-stimulating treatment options with their provider, since Bellafill competes with biostimulatory injectables such as Sculptra and Radiesse in the longevity category. Ongoing research on collagen-stimulating agents and their molecular mechanisms continues to shape how clinicians understand and compare biostimulatory dermal fillers including Bellafill.